Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Rating of “Buy” by Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned an average recommendation of “Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $66.00.

Several research analysts have recently weighed in on MAZE shares. JPMorgan Chase & Co. boosted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. HC Wainwright boosted their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Finally, BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $28.12 on Friday. The company’s 50-day moving average price is $26.88 and its 200-day moving average price is $34.89. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.56 billion, a P/E ratio of -11.11 and a beta of 2.14. Maze Therapeutics has a twelve month low of $12.81 and a twelve month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, sell-side analysts forecast that Maze Therapeutics will post -2.73 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00. Following the completion of the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 141,470 shares of company stock worth $3,887,939 in the last quarter. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics during the fourth quarter worth $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics in the fourth quarter valued at $43,000. California State Teachers Retirement System raised its position in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.